Given that the high doses of intravenously administered EVs increase the risk of fatal pulmonary embolism in mice,31 CD38‐EVs‐DoxMNs offer a safer alternative of delivery system for targeted EV delivery. This evidence concerns the gene CD38 and pulmonary embolism.